Australia markets closed

Seer, Inc. (SEER)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
33.14-0.63 (-1.87%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close33.77
Open33.75
Bid32.01 x 1000
Ask33.98 x 1100
Day's range32.69 - 34.21
52-week range26.48 - 86.55
Volume244,418
Avg. volume557,247
Market cap2.033B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date10 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est59.33
  • Seer Reports First Quarter 2021 Financial Results
    GlobeNewswire

    Seer Reports First Quarter 2021 Financial Results

    Second Phase of Commercialization Advances with the Addition of Multiple Limited Release Customers REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2021. “I am so incredibly proud of and amazed by our team for the progress we have made this quarter,” said Omid Farokhzad, Chair and Chief Executive Officer. “Unbiased, deep, rapid proteomics at scale will pave the way for broad-scale and novel biological insight – with incredible impact across science and medicine. We look forward to continuing to build our commercial momentum throughout 2021 as we bring the next phase in omics to labs around the globe.” Recent Highlights Advanced phase two of our three-phase commercial plan by signing agreements with multiple Limited Release customersCompleted installation at Salk Institute, bringing total number of active collaboration sites to fourOHSU Knight Cancer Institute and the Broad Institute successfully completed their initial pilot studies and are progressing toward larger-scale follow-on studiesStrengthened leadership team with the addition of Kenny Ross as VP Operations and QualityDoubled the size of Redwood City headquarters with a new lease to support growing organization First Quarter 2021 Financial Results Revenue was $62,000 for the three months ended March 31, 2021, as compared to $177,000 for the three months ended March 31, 2020. The decrease was due to less activity associated with our Small Business Innovation Research grant from the NIH. Operating expenses were $16.6 million for the first quarter of 2021, as compared to $6.0 million for the corresponding prior year period. The increase in expenses was driven by higher employee compensation costs and other expenses related to being a publicly traded company, as well as an increase in product development expenses related to our Proteograph Product Suite. Net loss was $16.4 million for the first quarter of 2021, as compared to $5.5 million for the corresponding prior year period. Cash, cash equivalents and investments were approximately $531 million as of March 31, 2021. Webcast Information Seer will host a conference call to discuss the first quarter 2021 financial results on Monday, May 10, 2021 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event. About Seer Seer is a life sciences company developing transformative products that open up a new gateway to the proteome. Seer is commercializing its Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be adopted by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures.For more information, please visit www.seer.bio. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding our timing and ability to enable unbiased, deep and rapid proteomics available at scale. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Quarterly Report on Form 10-Q, to be filed with the SEC on May 10, 2021, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact:Carrie Mendivilinvestor@seer.bio Media Contact:Karen Possematopr@seer.bio Seer, Inc.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share amounts)(unaudited) Three Months Ended March 31, 2021 2020 Revenue$62 $177 Operating expenses: Research and development 6,227 4,222 Selling, general and administrative 10,333 1,780 Total operating expenses 16,560 6,002 Loss from operations (16,498) (5,825)Other income (expense): Interest income 69 332 Net loss $(16,429) $(5,493) Net loss per share attributable to common stockholders, basic and diluted $(0.27) $(0.61)Weighted-average common shares outstanding, basic and diluted 59,887,842 8,944,284 Seer, Inc.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited) March 31, 2021 2020 ASSETS Current assets: Cash and cash equivalents $445,763 $333,585 Investments 85,379 98,278 Inventory 1,541 551 Other receivables 412 163 Other receivables, related parties 101 99 Prepaid expenses and other current assets 3,041 452 Total current assets 536,237 433,128 Property and equipment, net 8,682 8,441 Restricted cash 343 343 Other assets 377 407 TOTAL ASSETS $545,639 $442,319 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $1,933 $2,115 Accrued expenses 5,021 5,543 Deferred revenue 256 250 Deferred rent, current 186 186 Total current liabilities 7,396 8,094 Deferred rent, net of current portion 1,884 1,899 Other noncurrent liabilities 589 717 Total liabilities 9,869 10,710 Commitments (Note 10) Stockholders’ equity: Preferred stock — — Common stock 1 1 Additional paid-in capital 607,531 486,915 Accumulated other comprehensive income 28 54 Accumulated deficit (71,790) (55,361) Total stockholders’ equity 535,770 431,609 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $545,639 $442,319

  • Seer to Present at the BofA Securities 2021 Healthcare Conference
    GlobeNewswire

    Seer to Present at the BofA Securities 2021 Healthcare Conference

    REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating virtually in the upcoming BofA Securities 2021 Healthcare Conference. Seer’s management is scheduled to participate in a fireside chat on Thursday, May 13 at 10:15 a.m. Pacific Time / 1:15 p.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference. About SeerSeer is a life sciences company developing transformative products that open up a new gateway to the proteome. Seer is commercializing its Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be adopted by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio. Investor ContactCarrie Mendivilinvestor@seer.bio Media ContactKaren Possematopr@seer.bio

  • Seer to Report First Quarter Financial Results on May 10, 2021
    GlobeNewswire

    Seer to Report First Quarter Financial Results on May 10, 2021

    REDWOOD CITY, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 10, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event. About SeerSeer is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph™ Product Suite, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph Product Suite to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that is broadly available to life sciences researchers. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio. Investor ContactCarrie Mendivilinvestor@seer.bio Media ContactKaren Possematopr@seer.bio